ALNY vs. CRL: Alnylam Pharmaceuticals vs. Charles River Laboratories Stock Comparison

Company Profile

Alnylam Pharmaceuticals (ALNY) and Charles River Laboratories (CRL) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but ALNY is classified in Biotechnology while CRL is classified in Life Sciences Tools & Services.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Charles River Laboratories (CRL) has an aggressive beta of 1.33, indicating higher sensitivity to broad-market moves, while Alnylam Pharmaceuticals (ALNY) is defensive at 0.45 and tends to be less market-sensitive — they sit on opposite ends of the beta spectrum.

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Alnylam Pharmaceuticals (ALNY) at 138.07% clears its industry range for ROE, a sharper capital-efficiency signal than Charles River Laboratories (CRL) at 1.27%, which is closer to a typical peer reading.

Alnylam Pharmaceuticals (ALNY) at 52.85% converts revenue to bottom-line profit above its industry’s benchmark range, while Charles River Laboratories (CRL) at 1.01% keeps roughly the typical share for its industry.

Both Alnylam Pharmaceuticals (ALNY) at 23.72% and Charles River Laboratories (CRL) at 23.42% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

Profitability Metrics

Growth

Alnylam Pharmaceuticals (ALNY) at 65.19% sits in the top revenue growth quartile, while Charles River Laboratories (CRL) at -0.85% is in the bottom quartile, showing a clear gap in revenue momentum.

Only one side can be read here: Charles River Laboratories (CRL) reports EPS growth of -1,555.00%, ranked against its industry; Alnylam Pharmaceuticals (ALNY) has no EPS growth figure this period.

Growth Metrics

Financial Strength

Alnylam Pharmaceuticals (ALNY) at 2.48 keeps current ratio within its industry’s typical mid-range, while Charles River Laboratories (CRL) at 1.41 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for CRL.

Both Alnylam Pharmaceuticals (ALNY) at 0.83 and Charles River Laboratories (CRL) at 0.87 lean more heavily on debt funding than most peers, landing in the higher-leverage quartile of their industries.

Financial Strength Metrics

Dividends

Neither Alnylam Pharmaceuticals (ALNY) nor Charles River Laboratories (CRL) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

Neither Alnylam Pharmaceuticals (ALNY) nor Charles River Laboratories (CRL) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

Dividend Metrics

Valuation

Alnylam Pharmaceuticals (ALNY) at 7.88 sits in the cheaper P/E ratio quartile, while Charles River Laboratories (CRL) at 366.87 trades above its peer range — a wide earnings-valuation gap relative to industry peers.

On P/S ratio, both Alnylam Pharmaceuticals (ALNY) at 4.17 and Charles River Laboratories (CRL) at 4.07 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.

On P/B ratio, both Alnylam Pharmaceuticals (ALNY) at 5.79 and Charles River Laboratories (CRL) at 5.01 are valued close to their industries’ norm against book — neither stands out from peers.

Valuation Metrics